High-Risk Drug Classes and Interaction Concerns Not all medications are equally affected when used alongside GLP-1 therapies
Here, we report high-resolution cryo-EM structures of the GHSR-G i signaling complex with ghrelin and the non-peptide agonist ibutamoren as an investigational new drug
This only applies to oral BPC 157, since if youre injecting it, the form doesnt matter because it bypasses digestion entirely
A clinical study further supports that co-administration of GIP receptor agonists with GLP-1RAs reduces nausea and vomiting incidence, potentially via neuronal interactions in the hypothalamus and brainstem, though diarrhea rates remain comparable (Knop et al., 2024)
Oral BPC157 has been evaluated in models of gastric ulcers, colitis, and gut permeability, where it has shown protective and prohealing effects on the mucosal lining
FormBlends provides compounded semaglutide and tirzepatide